Login to Your Account


'Back to the Future' as GSK Hopes to Boost Innovation

By Nuala Moran
Staff Writer

Wednesday, February 8, 2012
LONDON – By splitting its internal research effort into dozens of small teams, with each focusing on a particular disease or pathway, GlaxoSmithKline plc is on track to solve its productivity woes and push its return on investment in R&D to 14 percent.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription